Dilaforette’s submission is entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’ under session for non-malignant hematopoetic disorders.
The 21st Congress of the European Hematology Association is to take place on 9-12 June 2016 at The Bella Center, Center Boulevard 5, Copenhagen. The poster (P756) will be presented by Dr. Maria Lindgren on Saturday 11 June between 17.30 and 19.00.
Dilaforette is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East (NCT02515838).
For further information, please contact:
Christina Herder, CEO:
Tel: +46 70 374 71 56
E-mail: christina.herder@dilaforette.se
David Dible/ Pip Batty, Citigate Dewe Rogerson
Tel: +44 20 7638 9571
E-mail: david.dible@citigatedr.co.uk
TO THE EDITORS
About Dilaforette AB
Dilaforette is a Swedish biotech company developing sevuparin - a new drug to treat people suffering from Sickle Cell Disease (SCD) – a painful, inherited blood disorder affecting millions of people around the globe. Sickle Cell Disease patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain and the amount of time they will need to spend in hospital. Dilaforette plans to develop a formulation of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care.
Dilaforette is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB. For more information, please visit www.dilaforette.se
About Sevuparin
Sevuparin is an innovative, proprietary polysaccharide drug, which has the potential to restore blood flow and prevent further microvascular obstructions, caused by abnormal blood cells in SCD patients. With its anti-adhesive properties, sevuparin could thereby offer treatment of the underlying cause of vaso-occlusive crisis (VOC) in SCD patients, with earlier pain relief, shorter hospital stay, reduced need of opioids and improved quality of life. Dilaforette is currently enrolling patients in a Phase II study with the aim to present data during second half of 2016. Sevuparin has been granted Orphan Drug designations in both EU and US for treatment of SCD.
